[1]张 帆,刘睿华,孙 维,等.草酸艾司西肽普兰联合曲唑酮治疗抑郁症126例疗效观察*[J].陕西医学杂志,2020,49(10):1332-1335.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.035]
　ZHANG Fan,LIU Ruihua,SUN Wei,et al.Efficacy of escitalopram oxalate combined with trazodone in treatment of 126 patients with depression[J].,2020,49(10):1332-1335.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.035]
点击复制

草酸艾司西肽普兰联合曲唑酮治疗抑郁症126例疗效观察*
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
49
期数:
2020年10期
页码:
1332-1335
栏目:
药物与临床
出版日期:
2020-10-05

文章信息/Info

Title:
Efficacy of escitalopram oxalate combined with trazodone in treatment of 126 patients with depression
作者:
张 帆1; 刘睿华1;  孙 维1; 宋金鹏2△; JENNIFER Johnson3(美国)
1.陕西省咸阳核工业二一五医院(咸阳 712000); 2.陕西省宝鸡市康复医院(宝鸡 721001)；3.休斯敦大学心理学系(德克萨斯州 77204)
Author(s):
ZHANG Fan; LIU Ruihua; SUN Wei; et al.
215 Hospital of Nuclear Industry,Xianyang City,Shaanxi Province(Xianyang 712000)
关键词:
草酸艾司西酞普兰;  曲唑酮;  抑郁症;  焦虑;  联合治疗;  临床疗效
Keywords:
Escitalopram oxalate;  Trazodone;  Depression;  Anxiety;  Combination therapy;  Clinical efficacy
分类号:
R749.4
DOI:
DOI:10.3969/j.issn.1000-7377.2020.10.035
文献标志码:
A
摘要:
目的:观察草酸艾司西酞普兰联合曲唑酮治疗抑郁症患者的临床疗效。方法: 收集126例抑郁症患者,随机数字表法将患者分成三组,分别给予草酸艾司西酞普兰(A组,n=43),曲唑酮(B组,n=43)及草酸艾司西酞普兰联合曲唑酮(C组,n=43)治疗2个月,采用汉密尔顿焦虑(HAMA)量表和汉密尔顿抑郁(HAMD)量表评定治疗后疗效; 使用副反应(TESS)量表检测药物的副作用; 生活质量综合评定(GQOLI)量表检测患者治疗后的生活质量。结果:与治疗前相比,三组患者治疗后HAMA评分和HAMD评分均显著降低,差异具有统计学意义(P<0.05); C组与A组和B组相比,HAMA评分和HAMD评分降低更明显(P<0.05)。进一步分析TESS评分和GQOLI评分结果显示,与治疗前相比,三组患者治疗后TESS评分和GQOLI评分均显著降低,差异具有统计学意义(P<0.05); C组与A组和B组相比,TESS评分降低明显,GQOLI评分升高更明显(P<0.05)。结论:草酸艾司西酞普兰联合曲唑酮能够有效改善患者焦虑和抑郁症状,联合用药效果显著优于各自单独用药,且药物不良反应少,生活质量改善更明显。
Abstract:
Objective:To observe the clinical efficacy of escitalopram oxalate combined with trazodone in the treatment of patients with depression.Methods:A total of 126 patients with depression were collected and divided into three groups by random number table method.They were given escitalopram oxalate(group A,n=43),trazodone(group B,n=43)and escitalopram oxalate combined with trazodone(group C,n=43)for 2 months.The Hamilton anxiety scale(HAMA)and Hamilton depression scale(HAMD)were used to evaluate the post-treatment efficacy.The side effect scale(TESS)was used to detect the side effects of drugs.The comprehensive quality of life scale(GQOLI)was used to measure the quality of life of patients after treatment.Results:After treatment,the HAMA and HAMD scores of the three groups were significantly reduced compared with that before treatment(P<0.05),and those of Group C were lower than those of Group A and Group B(P<0.05).Further analysis showed that the TESS and GQOLI scores of the three groups after treatment were significantly reduced compared with that before treatment(P<0.05),and the TESS score of Group C was lower than that of Group A and Group B,and the GQOLI score was higher than that of Group A and Group B(P<0.05).Conclusion:Escitalopram oxalate combined with trazodone can effectively improve patients' anxiety and depression symptoms.The combined effect is significantly better than that of each drug alone,and the side effects of the drug are less,and the quality of life is improved more obviously.

参考文献/References:

[1] 石文英,班 杰,李铁堂,等.相关研究进展综述[J].中华流行病学杂志,2018,39(2):245-248.
[2] Liu DD,Chu SF,Chen C,et al.Research progress in stroke-induced immunodepression syndrome(SIDS)and stroke-associated pneumonia(SAP)[J].Neurochemistry International,2018(114):42-54.
[3] Fried EI.Moving forward:how depression heterogeneity hinders progress in treatment and research[J].Expert Review of Neurotherapeutics,2017,17(5):423.
[4] Schlosser DA,Campellone TR,Truong B,et al.The feasibility,acceptability,and outcomes of PRIME-D:a novel mobile intervention treatment for depression[J].Depression & Anxiety,2017,34(6):546.
[5] 袁 磊,万伟祖,杨进平,等.逍遥散联合艾司西酞普兰治疗卒中后抑郁的疗效及对血清Hcy、Mcrp水平的影响[J].陕西中医,2015,36(2):151-153.
[6] 王锦辉,王建华,刘洪伟,等.柴胡加龙骨牡蛎汤加减治疗肿瘤后抑郁50例[J].陕西中医,2016,37(9):1205-1206.
[7] 李 继,王建军,李 烨,等.草酸艾司西酞普兰对脑卒中后抑郁、认知及神经功能的影响[J].河北医科大学学报,2017,38(5):589-592.
[8] Xu JH,Jiang P.Efficacy of escitalopram oxalate for patients with post-stroke depression[J].Medicine,2018,97(14):e0219.
[9] Sheladia S,Patel B.Determination of escitalopram oxalate and L-Methylfolate in tablet by spectrophotometric and reverse phase high-performance liquid chromatographic methods.[J].Journal of Chromatographic Science,2017,55(5):550-555.
[10] 刘玉路,赵静囡,李 洋,等.米氮平联合草酸艾司西酞普兰片治疗抑郁症的临床疗效及安全性评价[J].当代医学,2017,23(30):115-116.
[11] 刘连忠,张 娟.奥氮平与草酸艾司西酞普兰联合治疗对抑郁症患者血清微量元素及神经功能相关因子的影响[J].解放军预防医学杂志,2017,35(7):100-102.
[12] 陈建波,贾晓妮,权 伟,等.舒肝解郁胶囊合并草酸艾司西酞普兰对抑郁症患者焦虑、抑郁状态疗效临床研究[J].国际精神病学杂志,2017,44(4):635-637.
[13] 李 杨,谢宇宽,江桂芳,等.小剂量奥氮平联合氟西汀治疗重度抑郁症疗效及安全性评价[J].临床合理用药杂志,2017,10(22):17-18.
[14] 朴美香.氟西汀联合小剂量奥氮平治疗重度抑郁症的临床观察[J].中国卫生标准管理,2017,8(24):80-82.
[15] Yohn CN,Gergues MM,Samuels BA.The role of 5-HT receptors in depression[J].Molecular Brain,2017,10(1):28.
[16] Philippe TJ,Vahidansari F,Donaldson ZR,et al.Loss of MeCP2 in adult 5-HT neurons induces 5-HT1A autoreceptors,with opposite sex-dependent anxiety and depression phenotypes[J].Sci Rep,2018(8):5788.
[17] Lax NC,Parker SJ,Hilton J,et al.Cyanobacterial extract with serotonin receptor subtype 7(5-HT7R)affinity modulates depression and anxiety-like behavior in mice[J].Synapse,2018,72(11):e22059.
[18] 刘玉路,赵静囡,李 洋,等.米氮平联合草酸艾司西酞普兰片治疗抑郁症的临床疗效及安全性评价[J].当代医学,2017,23(30):105-106.
[19] 彭保全,钱 琳,段文涛.对重度抑郁症采用喹硫平、曲唑酮进行联合治疗的效果观察[J].北方药学,2017,14(10):35.
[20] 佚 名.曲唑酮联合有氧运动治疗更年期抑郁症的疗效观察[J].西南国防医药,2017,27(4):374-376.
[21] 杨 洁,王 刚.新型5-羟色胺再摄取抑制剂的抗抑郁治疗:多受体效应与临床作用[J].中华精神科杂志,2018,51(2):145.
[22] 刘连忠,张 娟.奥氮平与草酸艾司西酞普兰联合治疗对抑郁症患者血清微量元素及神经功能相关因子的影响[J].解放军预防医学杂志,2017,35(7):100-102.
[23] 杨 洁,王 刚.新型5-羟色胺再摄取抑制剂的抗抑郁治疗:多受体效应与临床作用[J].中华精神科杂志,2018(2):145-148.
[24] 柏 林,闫晶晶,王瑞芳.草酸艾司西酞普兰联合喹硫平片治疗抑郁症合并高血压的疗效与安全性分析[J].中国继续医学教育,2017,9(20):157-158.
[25] 田 娟,李娟娟,李 园,等.草酸艾司西酞普兰联合拉莫三嗪治疗儿童癫痫合并抑郁症的疗效及安全性[J].国际精神病学杂志,2017(6):1051-1053.

备注/Memo

备注/Memo:
*陕西省重点研发计划一般项目-社会发展领域(2018SF-143)
更新日期/Last Update: 2020-10-10